CAS: 187235-37-6; (S)-2-Nitro-6-((4-(Trifluoromethoxy)Benzyl)Oxy)-6,7-Dihydro-5H-Imidazo[2,1-B][1,3]Oxazine

上下游产品

(S)-2-硝基-6,7-二氢-5H-咪唑并[2,1-B][1,3]恶嗪-6-醇 (S)-2-Nitro-6,7-Dihydro-5H-Imidazo[2,1-B][1,3]Oxazin-6-Ol 187235-08-1

4-三氟甲氧基溴苄置于3-((3,5-Bis(Trifluoromethyl)Phenyl)Amino)-4-(((S)-3,3-Dimethyl-1-((R)-2-Methyl-2-(Phenanthren-9-yl)Pyrrolidin-1-yl)-1-Oxobutan-2-yl)Amino)Cyclobut-3-Ene-1,2-Dione,Sodium Hydride,三乙胺,Sodium Iodide体系中,用 2-甲基四氢呋喃,甲基叔丁基醚,N,N-二甲基甲酰胺,Mineral Oil 用作溶剂,化学反应 60.52H,反应生成(S)-6,7-二氢-2-硝基-6-[[4-(三氟甲氧基)苯基]甲氧基]-5H-咪唑并[2,1-B][1,3]恶嗪
参考文献:氧杂环丁烷的高度对映选择性,氢键供体催化加成
标题:氧杂环丁烷的高度对映选择性,氢键供体催化加成
摘要:精确设计的手性方酰胺衍生物可促进三甲基溴硅烷 (Tmsbr) 与多种 3-取代和 3,3-二取代氧杂环丁烷的高度对映选择性加成.该反应提供了从容易获得的非手性前体中直接,普遍地获得具有合成价值的 1,3-溴醇结构单元的方法.该产物很容易通过亲核取代和过渡金属催化的交叉偶联反应来制备.对映选择性催化氧杂环丁烷开环被用作 Pretomanid 的三步克级合成的一部分,Pretomanid 是最近批准的用于治疗多重耐药结核病的药物.重原子动力学同位素效应(kie)研究与溴化物从氢键供体(hbd)催化剂到活化氧杂环丁烷的对映体测定一致.虽然溴离子的亲核性预计会因与 Hbd 结合而减弱,但通过阴离子抽象增强 Tmsbr 试剂的路易斯酸度可实现总体速率加速.
Doi:10.1021/jacs.0C03991

专利信息

专利号:US-9908876-B2
优先权日:2009-11-05
标 题:Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same
发明人：MILLER MARVIN J; MORASKI GARRETT C; MARKLEY LOWELL D; DAVIS GEORGE E
权利人:UNIV NOTRE DAME DU LAC
摘要:Embodiments relate to the field of chemistry and biochemistry, and, more specifically, to imidazopyridine compounds, synthesis thereof, and methods of using same. Disclosed herein are various imidazo[1,2-a]pyhdine compounds and methods of using the novel compounds to treat or prevent tuberculosis in a subject or to inhibit fungal growth on plant species. Other embodiments include methods of synthesizing imidazo[1,2-a]pyridine compounds, such as the disclosed imidazo[1,2-a]pyridine compounds.

专利号:US-2023242482-A9
优先权日:2019-07-26
标 题:Discovery, total synthesis, and bioactivity of doscadenamides
发明人：LUESCH HENDRIK; LIANG XIAO; MATTHEW SUSAN; KWAN JASON C; CHEN QI-YIN; PAUL VALERIE J
权利人:UNIV FLORIDA; SMITHSONIAN INST
摘要:The invention is directed towards compounds (e.g., Formulae (I)-(IX)), their mechanism of action, processes to prepare the compounds, methods of activating quorum sensing signaling activity, and methods of treating diseases and disorders using the compounds described herein (e.g., Formulae (I)-(IX)).

专利号:CN-107915747-A
优先权日:2017-11-17
标 题:Synthesis of PA‑824

专利号:US-2022281816-A1
优先权日:2019-07-26
标题 :Discovery, total synthesis, and bioactivity of doscadenamides

专利号:WO-2025096495-A1
优先权日:2023-10-30
标 题 :Aryl fluorosulfate-based inhibitors as novel antitubercular agents
发明人：YANG BAIYUAN; MCNAMARA CASE W; CHATTERJEE ARNAB K; PETRASSI H MICHAEL; SHARPLESS K BARRY; QIN BO; SUKHEJA PARIDHI; LOVE MELISSA; WOODS ASHLEY; LIU DONGDONG
权利人:SCRIPPS RESEARCH INST
摘要:The disclosure provides the identification and development of a first-in-class, small-molecule inhibitor (Compound 95) of Polyketide synthase 13 (Pks13), a critical node in cell wall biosynthesis for Mycobacterium tuberculosis (Mtb). Cell wall inhibitors are a critical component of TB treatment. Uniquely, the Compound 95 series has been shown to form a covalent adduct with serine residue 801 in the acyltransferase (AT) domain of Pks13. The inhibition of the Pks13 AT domain ultimately leads to disruption of mycolic acid synthesis, which is an essential component of the mycobacterial cell wall. While Pks13 is recognized as a high-value drug target, there are no Pks13 inhibitors in development and Compound 95 represents a new class of inhibitors for TB treatment.

专利号:WO-2011057145-A2
优先权日:2009-11-05
标题 :Imidazo[1,2-a] pyridine compounds, synthesis thereof, and methods of using same